Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG | Q16739 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.36 |
| ▸ | MET | P08581 | 11/20 | 0.36 |
| ▸ | KDR | P35968 | 5/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24003865 | 0.93 | PIK3CG (0.38) | UGCGPIK3CGMETKDR | |
| SCHEMBL30233095 | 0.93 | PIK3CG (0.38) | UGCGPIK3CGMETKDR | |
| SCHEMBL25820871 | 0.88 | MEN1 (0.39) | UGCGPIK3CGNPC1RAB9AGAA | |
| SCHEMBL30232527 | 0.86 | MET (0.38) | UGCGPIK3CGMETNPC1RAB9A | |
| SCHEMBL24003953 | 0.86 | MET (0.38) | UGCGPIK3CGMETNPC1RAB9A | |
| SCHEMBL25820876 | 0.86 | NPC1 (0.38) | UGCGPIK3CGMETKDRNPC1 | |
| SCHEMBL24003929 | 0.84 | CYP11B2 (0.39) | UGCGPIK3CGMETKDRNPC1 | |
| SCHEMBL24010141 | 0.83 | NPC1 (0.43) | UGCGPIK3CGNPC1RAB9AGRM2 | |
| SCHEMBL25185237 | 0.82 | CYP11B2 (0.42) | UGCGPIK3CGNPC1RAB9AGRM2 | |
| SCHEMBL26310656 | 0.81 | GRM2 (0.37) | UGCGPIK3CGGRM2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | UGCG 1369/4885PIK3CG 13/4885MET 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.